Eisai Co., Ltd. (ESAIY)
| Market Cap | 8.03B |
| Revenue (ttm) | 5.04B |
| Net Income (ttm) | 373.95M |
| Shares Out | n/a |
| EPS (ttm) | 1.31 |
| PE Ratio | 21.48 |
| Forward PE | n/a |
| Dividend | 1.09 (15.25%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 509 |
| Average Volume | 304,123 |
| Open | 6.84 |
| Previous Close | 7.08 |
| Day's Range | 6.84 - 7.14 |
| 52-Week Range | 5.94 - 11.68 |
| Beta | -0.16 |
| RSI | 58.51 |
| Earnings Date | May 15, 2025 |
About Eisai
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a... [Read more]
Full Company ProfileFinancial Performance
In 2023, Eisai's revenue was 741.75 billion, a decrease of -0.36% compared to the previous year's 744.40 billion. Earnings were 42.41 billion, a decrease of -23.50%.
Financial numbers in JPY Financial StatementsNews
EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease
The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat mild cognitive impairment in the early stages of Alzheimer's disease.
EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug
European Union's human medicines committee (CHMP) said on Friday it is not updating its opinion on Eisai and Biogen's Alzheimer's drug Leqembi, after it recommended its approval in November.
Eisai: Will Have No Problem Hitting Leqembi Forecasts
Leqembi's growth is strong, and 2024 forecasts are conservative; we expect it to easily surpass expectations, adding significant EBITDA and reducing valuation multiples. Eisai's valuation looks attrac...
Eisai Co., Ltd. (ESALF) Q3 2024 Earnings Call Transcript
Eisai Co., Ltd. (OTCPK:ESALF) Q3 2024 Earnings Call Transcript February 7, 2025 1:00 AM ET Company Participants Haruo Naito - Representative Corporate Officer & CEO Terushige Iike - Executive Vice Pre...
Europe to review safety data for Eisai-Biogen Alzheimer's drug
The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's Alzheimer's drug Leqembi, the agency said on Friday.
US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's Alzheimer's drug Leqembi, the companies said on Monday.
Merck and Eisai's cancer drugs fail to improve overall survival in late-stage trial
Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve overall survival in patients with a type of esophageal cancer in a late-stage tri...
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
TOKYO--(BUSINESS WIRE)-- #IVD--Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office: Minato-ku, Tokyo), a wholly-owned subsidiary of H.U. Group Holdings, Inc. (Chairman, President and...
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachuset...
EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen
The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with early Alzheimer's disease, months after the agency first rejected the treatm...
Eisai: Still Relatively Modest Market-Implied Expectations For Leqembi
Leqembi has just started its commercial journey, and in order to achieve an appropriate or even discounted multiple, relatively modest penetration of the drug in the US would be needed. Lenvima is als...
Eisai Co., Ltd. (ESALF) Q2 2025 Earnings Call Transcript
Eisai Co., Ltd. (OTCPK:ESALF) Q2 2025 Earnings Conference Call November 8, 2024 1:00 AM ET Company Participants Haruo Naito - Representative Corporate Officer and CEO Akiko Nakahama - VP-Chief Portfol...
Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 - March 2025). Sales now expected to reach JPY 42.5 billion
STOCKHOLM , Nov. 7, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated their revenue outlook for Leqembi for their 2024 fiscal year (FY), which runs from...
Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
STOCKHOLM , Oct. 31, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License Applicat...
Eisai will request reconsideration of initial decision for lecanemab in Australia
STOCKHOLM , Oct. 16, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia issued a public stat...
UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug
Alzheimer's patients in Britain's state-run health service is unlikely to get access to Eisai and Biogen's new Leqembi drug, after it was approved by the country's regulator but deemed too expensive f...
Week In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED
Eisai Pharma collaborates with SEED to develop molecular glues for targeted protein degradation, with SEED eligible for up to $1.5 billion in milestones. Shanghai OcuMension acquires Chinese rights to...
Eisai Co Ltd (ESALF) Q1 2025 Earnings Call Transcript
Eisai Co Ltd (OTCPK:ESALF) Q1 2025 Results Conference Call August 2, 2024 2:00 AM ET Company Participants Mitsuru Shomon - Chief Financial Officer Keisuke Naito - Representative Corporate Officer and ...
Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest
The benefit of Eisai and Biogen's Alzheimer's drug Leqembi in patients with early-stage Alzheimer's appears to increase with continued use with no new safety issues, according to three-year data prese...
Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says
The breakthrough Alzheimer's drug Leqembi slowed disease progression in patients over three years, demonstrating the need for them to stay on the treatment long term. That's according to new data pres...
Shares of Japan's Eisai tumble after EU rejects Alzheimer's drug
Shares of Japan's Eisai tumbled 11% and were on track for their biggest one-day fall in three years on Monday, after the European Union's regulator rejected the drugmaker's Leqembi treatment for early...
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
European drug regulators rejected the Alzheimer's treatment Leqembi from Biogen and Eisai, creating another hurdle for the companies as they scramble to boost uptake of the therapy in the U.S. The Eu...
EU medicines regulator rejects Eisai-Biogen Alzheimer's drug
The European Union's drugs regulator on Friday rejected Eisai and Biogen's breakthrough treatment for early Alzheimer's disease, in a blow to the drugmakers as take-up in the U.S. has been slower than...
Eisai Selects Medidata's Clinical Data Studio to Enhance and Modernize Clinical Trial Efficiency and Patient Experience
NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced Eisai Inc. (“Eisai”), the U.S. pharmaceut...
EISAI TO BEGIN ENROLLING STUDY IN PATIENTS WITH NARCOLEPSY
NUTLEY, N.J. , July 8, 2024 /PRNewswire/ -- Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective o...